

Special Issue

Helicobacter pylori: Antibiotic Resistance and Treatment

Message from the Guest Editors

Treatments of *H. pylori* infection have been complicated by the increasing trends in antimicrobial resistance worldwide, primarily due to the overuse/misuse of antibiotics and the consequent selection of resistant clones. The role played by the frequent onset of adverse events during *H. pylori* therapies (that lead to low compliance) should not be underestimated, either. It is fundamental to carry out periodic assessments of *H. pylori* antibiotic resistance rates and to monitor treatments' efficacy. The development of new diagnostic tools (i.e., molecular methods to detect gene mutations related to antibiotic resistance) is a very interesting field to further explore. Last but not least, integration of probiotics or other co-adjuvants during antibiotic therapy seems to have a positive impact on therapy outcome. This Special Issue seeks manuscripts that improve our understanding of antimicrobial resistance in *H. pylori*. Submissions regarding resistance mechanisms, new methods, and new therapeutic approaches are especially encouraged. **Keywords:** *H. pylori* infection; antibiotic resistance mechanisms; use of coadjuvants for antibiotic treatments; epidemiology

Guest Editors

Dr. Ilaria Maria Saracino

Department of Experimental, Diagnostic and Specialty Medicine, School of Specialization in Microbiology and Virology, University of Bologna, 40138 Bologna, Italy

Dr. Matteo Pavoni

Department of Surgical and Medical Sciences, University of Bologna, 40138 Bologna, Italy

Deadline for manuscript submissions

closed (31 August 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/64813

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)